Search tips
Search criteria 


Logo of hsresearchLink to Publisher's site
Health Serv Res. 2001 October; 36(5): 885–909.
PMCID: PMC1089266

Evaluating the benefits of increasing measles immunization rates.


OBJECTIVE: To calculate the cost-effectiveness, expressed in dollars per quality-adjusted life years (QALY), of increasing measles immunization rates. DATA SOURCES/STUDY DESIGN: Published data were supplemented by expert opinion. We determined the cost savings and value of the health benefits from averting a single case of measles. Next we examined the U. S. data regarding the relationship between pre-school measles immunization and incidence rates. Finally, we calculated the cost-effectiveness of a program that would increase a locality's immunization rate to the point of disease elimination. PRINCIPAL FINDINGS: Averting a single case of measles, using "base case" assumptions, yields societal cost savings of $2,089 and an increase of 0.086 QALYs. Using a very low discount rate increases the total benefits to $2,251 in societal cost savings and 0.150 QALYs in health benefits. In general, programs to raise measles immunization rates are not cost-effective, except possibly during an outbreak of the disease or in areas with very low immunization rates. The extremely low measles incidence rates in the mid-1990s result in such programs having extremely high costs per QALY gained. CONCLUSIONS: Programs that are narrowly designed to increase immunization rates alone are not likely to be cost-effective. Yet these programs do have the potential to be cost-effective if the program design and evaluation also recognize the benefits associated with the primary and preventive care that can accompany immunizations. Such programs may also be cost-effective if they are components of a global eradication of measles.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Atkinson WL, Orenstein WA, Krugman S. The resurgence of measles in the United States, 1989-1990. Annu Rev Med. 1992;43:451–463. [PubMed]
  • de Quadros CA, Olivé JM, Hersh BS, Strassburg MA, Henderson DA, Brandling-Bennett D, Alleyne GA. Measles elimination in the Americas. Evolving strategies. JAMA. 1996 Jan 17;275(3):224–229. [PubMed]
  • Fairbrother G, Friedman S, DuMont KA, Lobach KS. Markers for primary care: missed opportunities to immunize and screen for lead and tuberculosis by private physicians serving large numbers of inner-city Medicaid-eligible children. Pediatrics. 1996 Jun;97(6 Pt 1):785–790. [PubMed]
  • Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302. [PubMed]
  • Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993 Apr-Jun;13(2):89–102. [PubMed]
  • Fryback DG, Lawrence WF., Jr Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making. 1997 Jul-Sep;17(3):276–284. [PubMed]
  • Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making. 1997 Jan-Mar;17(1):1–9. [PubMed]
  • Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics. 1987 Sep;80(3):319–329. [PubMed]
  • Hinman AR, Koplan JP. Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA. 1984 Jun 15;251(23):3109–3113. [PubMed]
  • Hopkins DR, Hinman AR, Koplan JP, Lane JM. The case for global measles eradication. Lancet. 1982 Jun 19;1(8286):1396–1398. [PubMed]
  • Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care. 1997 Nov;35(11):1109–1118. [PubMed]
  • King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994 May;13(5):394–407. [PubMed]
  • Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982 Apr;136(4):362–364. [PubMed]
  • Koplan JP, Schoenbaum SC, Weinstein MC, Fraser DW. Pertussis vaccine--an analysis of benefits, risks and costs. N Engl J Med. 1979 Oct 25;301(17):906–911. [PubMed]
  • Lanphear BP, le Cessie S, Atkinson WL, Watelet L. Association of livebirths and the resurgence of measles. Int J Epidemiol. 1997 Feb;26(1):204–211. [PubMed]
  • Nokes DJ, Williams JR, Butler AR. Towards eradication of measles virus: global progress and strategy evaluation. Vet Microbiol. 1995 May;44(2-4):333–350. [PubMed]
  • Orenstein WA, Bernier RH. Toward immunizing every child on time. Pediatrics. 1994 Oct;94(4 Pt 1):545–547. [PubMed]
  • Rodewald LE, Szilagyi PG, Humiston SG, Barth R, Kraus R, Raubertas RF. A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Pediatrics. 1999 Jan;103(1):31–38. [PubMed]
  • Rodewald LE, Szilagyi PG, Shiuh T, Humiston SG, LeBaron C, Hall CB. Is underimmunization a marker for insufficient utilization of preventive and primary care? Arch Pediatr Adolesc Med. 1995 Apr;149(4):393–397. [PubMed]
  • Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 9;276(14):1172–1177. [PubMed]
  • Schlenker TL, Bain C, Baughman AL, Hadler SC. Measles herd immunity. The association of attack rates with immunization rates in preschool children. JAMA. 1992 Feb 12;267(6):823–826. [PubMed]
  • Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 23;276(16):1339–1341. [PubMed]
  • Ware JE, Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995 Apr;33(4 Suppl):AS264–AS279. [PubMed]
  • White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health. 1985 Jul;75(7):739–744. [PubMed]
  • Williams BC. Immunization coverage among preschool children: the United States and selected European countries. Pediatrics. 1990 Dec;86(6 Pt 2):1052–1056. [PubMed]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust